Gyre Therapeutics (GYRE) Non-Current Deffered Revenue (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Non-Current Deffered Revenue of $840000.0 for Q1 2026, down 7.18% year-over-year from $905000.0 in Q1 2025, and down 1.41% quarter-over-quarter from $852000.0 in Q4 2025.
Gyre Therapeutics (GYRE) Non-Current Deffered Revenue (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Non-Current Deffered Revenue for 12 consecutive years, with $840000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Deffered Revenue fell 7.18% year-over-year to $840000.0; the TTM figure through Mar 2026 stood at $840000.0 (down 7.18% YoY), while the FY2025 annual figure was $852000.0, down 8.19% from the prior year.
- Non-Current Deffered Revenue retreated to $840000.0 in Q1 2026 per GYRE's latest filing, from $852000.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $928000.0 in Q4 2024 and bottomed at $118000.0 in Q4 2022.
- Historically, Non-Current Deffered Revenue has averaged $562363.6 across 5 years, with a median of $840000.0 in 2026.
- On a YoY basis, Non-Current Deffered Revenue climbed as much as 368.11% in 2025 and fell as far as 8.19% in 2025.
- Gyre Therapeutics' Non-Current Deffered Revenue stood at $118000.0 in 2022, then soared by 80.51% to $213000.0 in 2023, then soared by 335.68% to $928000.0 in 2024, then declined by 8.19% to $852000.0 in 2025, then retreated by 1.41% to $840000.0 in 2026.
- Business Quant data shows GYRE's Non-Current Deffered Revenue at $840000.0 in Q1 2026, $852000.0 in Q4 2025, and $866000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | 829,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 829,000.00 |
| Mar 31, 2026 | 840,000.00 |
| Dec 31, 2025 | 852,000.00 |
| Sep 30, 2025 | 866,000.00 |
| Jun 30, 2025 | 884,000.00 |
| Mar 31, 2025 | 905,000.00 |
| Dec 31, 2024 | 928,000.00 |
| Sep 30, 2024 | 185,000.00 |
| Jun 30, 2024 | 192,000.00 |
| Mar 31, 2024 | 203,000.00 |
| Dec 31, 2023 | 213,000.00 |
| Dec 31, 2022 | 118,000.00 |
| Dec 31, 2018 | 174,000.00 |
| Sep 30, 2018 | 161,000.00 |
| Jun 30, 2018 | 140,000.00 |
| Mar 31, 2018 | 135,000.00 |
| Dec 31, 2016 | 7,000.00 |
| Sep 30, 2016 | 18,000.00 |
| Jun 30, 2016 | 73,000.00 |
| Mar 31, 2016 | 183,000.00 |